In the model of adaptive resistance to MAPKi therapy in CRC, the combination of BRAFi+SRCi+TSC1ovr could further increase sensitivity to treatment and the rate of apoptosis by MAPK and mTOR signaling inhibition63. Here, MTOR is linked to colorectal carcinoma.